CTi Biopharma Corp Price Prediction

CTICDelisted Stock  USD 9.09  0.00  0.00%   
At the present time The value of RSI of CTi Biopharma's share price is above 80 suggesting that the stock is significantly overbought by investors. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards.

Oversold Vs Overbought

85

 
Oversold
 
Overbought
CTi Biopharma Corp stock price prediction is an act of determining the future value of CTi Biopharma shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of CTi Biopharma's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of CTi Biopharma and does not consider all of the tangible or intangible factors available from CTi Biopharma's fundamental data. We analyze noise-free headlines and recent hype associated with CTi Biopharma Corp, which may create opportunities for some arbitrage if properly timed.
It is a matter of debate whether delisted stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of CTi Biopharma based on different types of headlines from major news networks to social media. The CTi stock price prediction module provides an analysis of price elasticity to changes in media outlook on CTi Biopharma over a specific investment horizon. Using CTi Biopharma hype-based prediction, you can estimate the value of CTi Biopharma Corp from the perspective of CTi Biopharma response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in CTi Biopharma. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in CTi Biopharma to buy its stock at a price that has no basis in reality. In that case, they are not buying CTi because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

CTi Biopharma after-hype prediction price

    
  USD 9.09  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as delisted stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of CTi Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
6.666.6610.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as CTi Biopharma. Your research has to be compared to or analyzed against CTi Biopharma's peers to derive any actionable benefits. When done correctly, CTi Biopharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in CTi Biopharma Corp.

CTi Biopharma After-Hype Price Prediction Density Analysis

As far as predicting the price of CTi Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in CTi Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of CTi Biopharma, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

CTi Biopharma Estimiated After-Hype Price Volatility

In the context of predicting CTi Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on CTi Biopharma's historical news coverage. CTi Biopharma's after-hype downside and upside margins for the prediction period are 9.09 and 9.09, respectively. We have considered CTi Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
9.09
9.09
After-hype Price
9.09
Upside
CTi Biopharma is very steady at this time. Analysis and calculation of next after-hype price of CTi Biopharma Corp is based on 3 months time horizon.

CTi Biopharma Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as CTi Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CTi Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Delisted Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with CTi Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
 0.00  
0.00
 0.00  
 0.00  
8 Events / Month
16 Events / Month
In about 8 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
9.09
9.09
0.00 
0.00  
Notes

CTi Biopharma Hype Timeline

CTi Biopharma Corp is currently traded for 9.09. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. CTi is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at 0.0%. %. The volatility of related hype on CTi Biopharma is about 0.0%, with the expected price after the next announcement by competition of 9.09. About 83.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.54. CTi Biopharma Corp last dividend was issued on the 3rd of January 2017. The entity had 1:10 split on the 3rd of January 2017. Given the investment horizon of 90 days the next forecasted press release will be in about 8 days.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

CTi Biopharma Related Hype Analysis

Having access to credible news sources related to CTi Biopharma's direct competition is more important than ever and may enhance your ability to predict CTi Biopharma's future price movements. Getting to know how CTi Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how CTi Biopharma may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
RIGLRigel Pharmaceuticals(0.02)9 per month 0.00 (0.09) 5.41 (7.44) 25.53 
FBIOFortress Biotech 0.02 9 per month 3.96  0.01  10.10 (7.03) 24.66 
RVPHReviva Pharmaceuticals Holdings 0.05 6 per month 0.00 (0.08) 7.31 (7.79) 32.56 
OCUPOcuphire Pharma 0.04 9 per month 0.00 (0.21) 4.35 (5.04) 21.95 
PLXProtalix Biotherapeutics 0.07 6 per month 0.00 (0.14) 5.84 (4.55) 16.16 
MCRBSeres Therapeutics(0.09)8 per month 0.00 (0.25) 6.58 (7.83) 20.08 
CDTXCidara Therapeutics 0.02 8 per month 4.45  0  8.96 (6.52) 31.27 
IBRXImmunitybio 0.33 8 per month 7.47  0.08  10.94 (10.38) 46.63 
GRTXGalera Therapeutics(0.02)5 per month 5.50  0.01  14.29 (11.11) 49.76 
SELBSELB Old(0.02)3 per month 0.00 (0.1) 6.86 (5.45) 15.52 
PRTKParatek Pharmaceuticals 0.03 9 per month 0.57 (0.05) 0.92 (0.90) 3.64 
CRVSCorvus Pharmaceuticals(0.07)8 per month 0.00 (0.17) 5.38 (6.00) 18.48 
IMMPImmutep Ltd ADR 0.13 2 per month 0.00 (0.05) 5.56 (5.33) 18.34 
ICVXIcosavax(0.07)9 per month 1.28  0.15  8.15 (4.36) 50.81 
VSTMVerastem 0.85 8 per month 0.00 (0.02) 7.12 (5.63) 24.68 
IMGNImmunoGen(0.1)10 per month 0.70  0.13  5.69 (1.50) 84.35 
ICPTIntercept Pharmaceuticals 0.24 7 per month 1.31  0.12  4.60 (3.38) 83.17 
ELEVElevation Oncology(0.49)7 per month 3.90  0.12  13.28 (7.06) 34.99 
VKTXViking Therapeutics(5.37)12 per month 5.03  0.15  13.66 (9.60) 139.87 
TGTXTG Therapeutics(0.20)10 per month 0.00 (0.02) 4.12 (6.38) 33.52 
XFORX4 Pharmaceuticals 0.28 8 per month 4.09  0.12  10.47 (7.00) 37.52 
PDSBPDS Biotechnology Corp 0.05 9 per month 0.00 (0.08) 7.51 (9.16) 26.33 
MDGLMadrigal Pharmaceuticals 5.98 10 per month 0.00 (0.02) 8.89 (7.09) 24.70 

CTi Biopharma Additional Predictive Modules

Most predictive techniques to examine CTi price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for CTi using various technical indicators. When you analyze CTi charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About CTi Biopharma Predictive Indicators

The successful prediction of CTi Biopharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as CTi Biopharma Corp, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of CTi Biopharma based on analysis of CTi Biopharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to CTi Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to CTi Biopharma's related companies.

Story Coverage note for CTi Biopharma

The number of cover stories for CTi Biopharma depends on current market conditions and CTi Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that CTi Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about CTi Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

CTi Biopharma Short Properties

CTi Biopharma's future price predictability will typically decrease when CTi Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of CTi Biopharma Corp often depends not only on the future outlook of the potential CTi Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. CTi Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding114.7 M
Cash And Short Term Investments79.9 M
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Other Consideration for investing in CTi Stock

If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years